You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid-19: WHO seeks more data from Sputnik V makers for granting EUL

The World Health Organisation has sought some more data from developer of COVID-19 vaccine Sputnik V for according Emergency Use Listing status for the jab

Topics
Coronavirus Vaccine

Press Trust of India  |  Hyderabad 

Sputnik Light
Photo: Bloomberg

The World Health Organisation has sought some more data from Russia's Gamaleya National Research Institute of Epidemiology and Microbiology, developer of COVID-19 vaccine Sputnik V for according Emergency Use Listing status for the jab.

Sputnik V is currently manufactured in India and being sold by Dr Reddy's Laboratories under Emergency Use Authorisation route. According to WHO website, though several meetings were held as part of the process for EUL, the status of assessment column says On hold, awaiting completion of rolling submission. Anticipated date will be set once all data is submitted and follow-up of inspection observations completed, WHO said on the decision date for EUL. Back home, Panacea Biotec supplied the first shipment of the second component of the Russian Sputnik V vaccine manufactured by it for sale in India on September 7. This is the first batch of the second component produced and supplied by the company in India, the drug firm and the Russian Direct Investment Fund (RDIF) had said in a joint statement. RDIF has tied up with six Indian drug makers to manufacture Sputnik V and their supplies are expected to roll out by August or September, as senior official of Dr Reddy's had said earlier.

The global health body is currently reviewing Bharat Biotech's application for an Emergency Use Listing of its COVID-19 vaccine Covaxin.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, September 11 2021. 11:04 IST
RECOMMENDED FOR YOU